CRESCENT BIOPHARMA, INC. 8-K

What Happened

• Crescent Biopharma, Inc. filed a Form 8‑K (Item 2.02) on July 14, 2026, providing preliminary financial information for the quarter ended June 30, 2026. The company estimated cash and cash equivalents of approximately $171.6 million as of June 30, 2026.
• The company emphasized this figure is preliminary, unaudited, prepared by management, and subject to completion of financial closing procedures; PricewaterhouseCoopers LLP has not audited or reviewed the preliminary data.

Key Details

• Reported cash and cash equivalents: approximately $171.6 million (as of June 30, 2026).
• Filing type and date: Form 8‑K, Item 2.02 (Results of Operations and Financial Condition), filed July 14, 2026.
• Nature of the data: preliminary, unaudited management estimates; not a comprehensive statement of quarterly results and subject to change after closing and audit.
• Auditor disclaimer: PwC did not audit, review, examine, compile, or apply agreed‑upon procedures to the preliminary data and expressed no assurance.

Why It Matters

• Cash and cash equivalents are a key indicator of liquidity and short‑term financial flexibility; this preliminary $171.6M figure gives investors an early view of Crescent Biopharma’s cash position for the quarter ended June 30, 2026.
• Because the data are preliminary and unaudited, investors should treat the number as provisional until the company completes its quarter‑end close and releases formal, audited quarterly results or additional disclosures.